Biopharma SHAKTI - Strategy for Healthcare Advancement through Knowledge, Technology & Innovation
**Objective:** Position India as a global biomanufacturing hub by building an ecosystem for domestic production of biologics and biosimilars. **Budget:** ₹10,000 crore over 5 years. **Key Components:** - 3 new National Institutes of Pharmaceutical Education and Research (NIPERs) + upgrading 7 existing NIPERs - Network of 1,000+ accredited clinical trial sites across India - Strengthening CDSCO with dedicated scientific review cadre for global-standard approval timelines - Catalysing investments in advanced biomanufacturing facilities - Developing next-generation therapeutic capabilities for cancer, diabetes, autoimmune disorders **Beneficiaries:** Biopharma industry, patients needing affordable biologics, medical researchers, pharmaceutical education students. **Announced:** Union Budget 2026-27 (February 1, 2026).
- Biopharma SHAKTI has a budget of ₹10,000 crore over 5 years to position India as a global biomanufacturing hub for biologics and biosimilars.
- Includes establishment of 3 new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrading 7 existing NIPERs.
- Plans a network of 1,000+ accredited clinical trial sites across India.
- Strengthens CDSCO with a dedicated scientific review cadre for global-standard approval timelines.
- Develops next-generation therapeutic capabilities for cancer, diabetes, and autoimmune disorders.
- Announced in Union Budget 2026-27 (February 1, 2026), benefiting biopharma industry, patients, researchers, and pharmaceutical education students.
What is the objective of Biopharma SHAKTI?
Biopharma SHAKTI aims to position India as a global biomanufacturing hub by building an ecosystem for domestic production of biologics and biosimilars.
What is the budget for Biopharma SHAKTI?
The scheme has a total outlay of ₹10,000 crore over 5 years, announced in the Union Budget 2026-27 on 1 February 2026.
What are the key components of Biopharma SHAKTI?
Key components include 3 new NIPERs plus upgrading 7 existing NIPERs, a network of 1,000+ accredited clinical trial sites, and strengthening CDSCO with a dedicated scientific review cadre.
Which therapeutic areas does Biopharma SHAKTI focus on?
The scheme targets next-generation therapeutic capabilities for cancer, diabetes, and autoimmune disorders, while catalysing investments in advanced biomanufacturing facilities.
Who are the beneficiaries of Biopharma SHAKTI?
Beneficiaries include the biopharma industry, patients needing affordable biologics, medical researchers, and pharmaceutical education students at NIPERs across India.
Practice MCQs on this topic.
Reinforce your understanding with targeted MCQ practice on economy, governance, and current affairs.